Your session is about to expire
← Back to Search
IDH Mutant Targeted Therapies + Azacitidine for Acute Myeloid Leukemia
Study Summary
This trial will study two drugs, AG-120 and AG-221, in combination with azacitidine, to see if they are safe and effective in treating AML with IDH1 or IDH2 mutations.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 187 Patients • NCT02989857Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My AML developed from chronic myelogenous leukemia.I might have leukemia affecting my brain or spinal cord.There are other requirements or restrictions for participating in the study that are specified in the study protocol.I have been diagnosed with AML with more than 20% cancer cells in my bone marrow.I am diagnosed or suspected to have a specific type of leukemia.I have been treated with a drug targeting IDH1 or IDH2 mutation.I can take care of myself and am up and about more than half of my waking hours.I agree to have multiple bone marrow tests.
- Group 1: AG-120 + Azacitidine
- Group 2: AG-221 + Azacitidine
- Group 3: Azacitidine
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there precedent studies on AG-120's efficacy?
"AG-120 is being trialed in 212 active studies, the majority of which are in Phase 3. 34 of these trials are taking place in Edmonton, Alberta, but there are a total of 6539 locations running AG-120 trials."
At how many different places is this clinical trial being overseen?
"The list of institutions running this study includes the University of Chicago, Dana Farber Cancer Institute, City of Hope and 13 other locations."
Are there any vacant slots in this particular clinical trial?
"This specific trial is not currently seeking patients, as denoted by its inactive status on clinicaltrials.gov. This page was created on 6/3/2016 and updated for the last time 8/18/2022; however, there are many other medical trials (1733 at present) that may be of interest."
What are the conditions that AG-120 has been known to improve?
"AG-120 can be used to induction chemotherapy, refractory anemias, and leukemia, myelocytic, acute."
How many people will be included in this clinical research project?
"This specific study is no longer seeking participants. Although, there are many other trials (1521 for leukemia, myeloid, acute and 212 for AG-120) that might be of interest and are currently admitting patients."
Share this study with friends
Copy Link
Messenger